Maintaining of embryonated EGG supply for non-seasonal production of pandemic vaccine
Active Definitive Contract Awarded Last action
- Contract number
- 75A50125C00002
- Awardee
-
Sanofi Vaccines US Inc. UEI NCXBGGQ8YTU9
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $53,212,199
Award facts
- Contract value 67% obligated
-
- $53,212,199.00 Current, with exercised options
- $79,838,515.00 Potential, with all options
- Completion date 59% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- Q999 Medical- Other
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Swiftwater, PA 18370, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Davis-Bacon Act FAR subpart 22.4
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $26,612,706 | |
| Exercise an Option | $17,714,279 | |
| Original award | $8,885,214 |
About this award
The U.S. Office of the Assistant Secretary for Preparedness and Response awarded a modification to Sanofi Vaccines US Inc. (operating as Sanofi Pasteur Inc.) for the maintenance of embryonated egg supply to support non-seasonal production of pandemic vaccine. This modification, effective February 1, 2025, replaces the principal investigator from Kristin Kelly to Sarah Humphrey while keeping all other contract terms and conditions unchanged. The work will be performed at the contractor's facility in Swiftwater, Pennsylvania, with a ceiling value of $79.8 million under a cost-plus-fixed-fee structure. The contract is scheduled for completion by January 31, 2028, and no set-aside designation was used.
This award reflects the critical role that Sanofi Pasteur plays in supporting U.S. pandemic preparedness and vaccine infrastructure. As a major global vaccine manufacturer with established federal relationships across multiple agencies including the CDC, Department of Defense, and Department of Health and Human Services, the company has demonstrated substantial capacity to meet large-scale vaccine production requirements. The focus on maintaining embryonated egg supply—a key input for certain vaccine production methods—underscores the government's commitment to ensuring domestic surge capacity for pandemic vaccine manufacturing in response to potential public health emergencies.
Quick answers
Who was awarded contract 75A50125C00002?
75A50125C00002 was awarded to Sanofi Vaccines US Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on February 1, 2025.
How much is contract 75A50125C00002 worth?
The government has obligated $53,212,199 on 75A50125C00002. Its potential value, with all options, is $79,838,515.
Was contract 75A50125C00002 competed?
The extent of competition for 75A50125C00002 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award